We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1776
AN2 Therapeutics
ANTX
$217M
| $13K | ﹤0.01% |
12,237
| – | – |
|
|
IRBT
1777
DELISTED
iRobot
IRBT
| $12.9K | ﹤0.01% |
4,136
-716,261
| -99% | -$1.98M |
|
1778
Nuvation Bio
NUVB
$2.45B
| $12.9K | ﹤0.01% |
6,610
-3,946
| -37% | -$8.22K |
|
|
LADR
1779
Ladder Capital
LADR
$1.25B
| $12.9K | ﹤0.01% |
1,198
| – | – |
|
1780
Eagle Bancorp
EGBN
$842M
| $12.8K | ﹤0.01% |
+657
| New | +$12.2K |
|
1781
Cardlytics
CDLX
$23.6M
| $12.8K | ﹤0.01% |
778
+316
| +68% | +$5.46K |
|
1782
Erasca
ERAS
$6.82B
| $12.8K | ﹤0.01% |
10,070
-4,920
| -33% | -$6.59K |
|
1783
Colony Bankcorp
CBAN
$452M
| $12.7K | ﹤0.01% |
+770
| New | +$11.9K |
|
1784
Unity
U
$19.1B
| $12.7K | ﹤0.01% |
523
-3,968
| -88% | -$87.3K |
|
1785
Green Brick Partners
GRBK
$3.13B
| $12.6K | ﹤0.01% |
200
-93
| -32% | -$5.51K |
|
1786
Northeast Community Bancorp
NECB
$363M
| $12.5K | ﹤0.01% |
536
| – | – |
|
1787
Atea Pharmaceuticals
AVIR
$437M
| $12.4K | ﹤0.01% |
3,442
-579,287
| -99% | -$1.73M |
|
1788
Matsons
MATX
$6.64B
| $12.4K | ﹤0.01% |
111
+33
| +42% | +$3.61K |
|
1789
HSBC
HSBC
$352B
| $12.3K | ﹤0.01% |
203
| – | – |
|
1790
Seagate
STX
$192B
| $12.3K | ﹤0.01% |
+85
| New | +$8.8K |
|
1791
Progyny
PGNY
$1.98B
| $12.2K | ﹤0.01% |
556
-254
| -31% | -$5.57K |
|
|
FSFG
1792
DELISTED
First Savings Financial Group
FSFG
| $12.2K | ﹤0.01% |
+488
| New | +$12.5K |
|
1793
Vita Coco
COCO
$3.57B
| $12.2K | ﹤0.01% |
338
+111
| +49% | +$3.71K |
|
1794
United Parks & Resorts
PRKS
$1.93B
| $12.1K | ﹤0.01% |
257
-121
| -32% | -$5.4K |
|
1795
Replimune Group
REPL
$1.47B
| $12K | ﹤0.01% |
1,291
-423
| -25% | -$3.69K |
|
1796
SI-BONE Inc
SIBN
$861M
| $12K | ﹤0.01% |
+635
| New | +$10.5K |
|
1797
Universal Electronics
UEIC
$55.4M
| $11.9K | ﹤0.01% |
1,792
+817
| +84% | +$4.99K |
|
1798
Tecnoglass Holdings
TGLS
$1.79B
| $11.8K | ﹤0.01% |
153
+82
| +115% | +$6.36K |
|
1799
Forum Energy Technologies
FET
$897M
| $11.8K | ﹤0.01% |
606
+488
| +414% | +$7.9K |
|
1800
Enovis
ENOV
$1.43B
| $11.8K | ﹤0.01% |
376
-50
| -12% | -$1.65K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.